Recognition of R&D Expenses and Breakdown by Business
First written in FY2024-Q3. 2 of 5 entries say "Restated". Latest entry: FY2026.
42 other companies' latest entry also says "Other".
- FY2026Decline in research and development expenses and continuation of development activitiesAnnual report
「The main research and development activities during the current consolidated fiscal year comprised development costs for Medical Doc AI and an online medical consultation system in the Medical Platform business, and self-service payment terminals in the Smart Clinic business. The group mainly improved functions to enhance customer convenience, and research and development expenses amounted to ¥100.276 million.」
Development themes including Medical DOC AI, the online medical consultation system, self-service payment terminals and SMART One continued, while research and development expenses declined from ¥151.136 million in the previous fiscal year to ¥100.276 million. - FY2026-H1RestatedAnnual report
「Research and development expenses for the group as a whole during the current interim consolidated accounting period amounted to ¥61.048 million. By segment, ¥8.911 million was attributable to the Medical Platform business and ¥38.898 million to the Smart Clinic business. There were no material changes in the status of the group's research and development activities during the current interim consolidated accounting period.」
Research and development expenses of ¥61.048 million and the breakdown by business are presented, reconfirming that there were no material changes in the status of research and development activities. - FY2025AdvancedAnnual report
「The main research and development activities during the current consolidated fiscal year comprised development costs for Medical Doc AI and an online medical consultation system in the Medical Platform business, and self-service payment terminals in the Smart Clinic business. The group mainly improved functions to enhance customer convenience, and research and development expenses amounted to ¥151.136 million.」
Research and development expenses amounted to ¥151.136 million, with a breakdown including Medical DOC AI, the online medical consultation system, self-service payment terminals and SMART One. - FY2025-H1RestatedAnnual report
「Research and development expenses for the group as a whole during the current interim consolidated accounting period amounted to ¥77.995 million. By segment, ¥20.942 million was attributable to the Medical Platform business and ¥55.924 million to the Smart Clinic business. There were no material changes in the status of the group's research and development activities during the current interim consolidated accounting period.」
The breakdown of ¥77.995 million in research and development expenses by business is presented, with no material changes reported in the status of research and development activities. - FY2024-Q3First statedAnnual report
「Research and development expenses for the group as a whole during the nine-month period of the current consolidated fiscal year amounted to ¥38.336 million. By segment, ¥25.727 million was attributable to the Medical Platform business and ¥12.481 million to the Smart Clinic business.」
Research and development expenses for the nine-month period amounted to ¥38.336 million, comprising ¥25.727 million for the Medical Platform business and ¥12.481 million for the Smart Clinic business.